Noile-Immune Biotech Inc. (TYO:4893)

Noile-Immune Biotech Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,670	5,555	4,520	4,140	2,548
Cash & Short-Term Investments	4,670	5,555	4,520	4,140	2,548
Cash Growth	-15.93%	22.90%	9.18%	62.48%	-
Accounts Receivable	-	-	-	-	3
Other Receivables	62	66	-	53	48
Receivables	62	66	-	53	51
Inventory	8	20	3	4	10
Prepaid Expenses	29	38	27	25	21
Other Current Assets	6	38	34	3	29
Total Current Assets	4,775	5,717	4,584	4,225	2,659
Long-Term Investments	24	61	56	45	15
Other Long-Term Assets	1	-	1	1	-
Total Assets	4,800	5,778	4,641	4,271	2,674
Accounts Payable	-	1	-	-	-
Accrued Expenses	27	29	45	20	17
Current Income Taxes Payable	32	48	235	51	13
Other Current Liabilities	10	8	55	9	40
Total Current Liabilities	69	86	335	80	70
Other Long-Term Liabilities	7	6	7	6	6
Total Liabilities	76	92	342	86	76
Common Stock	4,047	4,045	2,787	2,537	1,346
Additional Paid-In Capital	4,025	4,023	2,765	2,515	1,324
Retained Earnings	-3,353	-2,389	-1,259	-872	-77
Comprehensive Income & Other	5	7	6	5	5
Shareholders' Equity	4,724	5,686	4,299	4,185	2,598
Total Liabilities & Equity	4,800	5,778	4,641	4,271	2,674
Net Cash (Debt)	4,670	5,555	4,520	4,140	2,548
Net Cash Growth	-15.93%	22.90%	9.18%	62.48%	-
Net Cash Per Share	107.86	133.96	115.40	108.06	71.75
Filing Date Shares Outstanding	43.3	43.3	39.58	38.31	35.51
Total Common Shares Outstanding	43.3	43.3	39.58	38.31	35.51
Working Capital	4,706	5,631	4,249	4,145	2,589
Book Value Per Share	109.09	131.33	108.60	109.23	73.16
Tangible Book Value	4,724	5,686	4,299	4,185	2,598
Tangible Book Value Per Share	109.09	131.33	108.60	109.23	73.16

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.